Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.
You may also be interested in...
GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.
Tokai Raises $23 Million In Series D Financing
The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound
Tokai Raises $23 Million In Series D Financing
The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound